Comparing the two second generation basal insulins in T1DM
Did you know that InRange* is the first randomised control trial to use Time-In-Range as the primary endpoint? The study compares the second generation basal insulin analogues Toujeo and insulin degludec 100U/mL in people with T1DM. Find out more in the InRange study below.
*The In-Range study has been sponsored by Sanofi
Always up to date?
Webinars, evidence, expert videos, peer-to-peer events… Do you want to be the first to know when new, relevant information is available? Let us know and we’ll send you a message.